BLUE Dragon Institute (KRS 0001094167, NIP 7011195181) is a Polish company, headquartered in Warszawa, Mazowieckie voivodeship. BLUE Dragon Institute operates in: Research and experimental development on social sciences and humanities (PKD 72.20.Z). Industry: Research and development. The company has been listed in the National Court Register since March 14, 2024.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - BLUE Dragon Institute
Identity
- Name
- BLUE Dragon Institute
- Legal form
- FUNDACJA
- Founded
- March 14, 2024
- Registry status as of
- July 27, 2026
- Latest entry
- July 27, 2026
- Founding act
- 27.02.2024
Articles of association history (2)
- February 27, 2024: 27.02.2024
- 1 MARCA 2025 R., ZMIANA §15 STATUTU
Activities
Other activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. NOWOGRODZKA, 50, 515, 00-695, WARSZAWA, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- WARSZAWA
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-57843-34841-AHGVR-22
Operational status - BLUE Dragon Institute
Founded
March 14, 2024
2 years in operation
Legal form
FUNDACJA
Registry: RejP
Headquarters
WARSZAWA
MAZOWIECKIE
Primary PKD
72.20.Z
Research and experimental development on social sciences and humani…
Share capital
N/A
Shareholders
N/A
Board
2 people
Sup. board: 4
Filed years
N/A
Registry entries
9
latest: July 27, 2026
No KPI data - financial statements and valuation are unavailable for this company.
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - BLUE Dragon Institute.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase on BCX-CM-J – potentially Europe's first veterinary cell-therapy drug based on mesenchymal stem cells, for dogs with osteoarthritis. Responses to the EMA's final questions are due in May 2026; a CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. A pre-commercial biotech: it closed 2024 with a PLN 14.9m loss on zero revenue and PLN 33.6m of cash at year-end. Trigon DM maintains a buy rating with a PLN 127.2 price target.
News
Captor Therapeutics: PLN 36m of cash at 30 September 2025, runway to mid-2026 – clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) – a pre-commercial biotech specialising in targeted protein degradation (TPD) – closed Q3 2025 with PLN 36m of cash and grants securing funding to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I, with the first patient dosed at the Barcelona Clinic Liver Cancer. CT-03, an MCL-1 degrader, is close to clinical entry. Without a new R&D partnership or share issue in 2026, the company will need additional financing.
